Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Go back to Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure| Amgen Inc (NASDAQ: AMGN) | Delayed: 344.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $344.72 | 52 Week High | $176.85 | |||
| Open | $344.72 | 52 Week Low | $133.64 | |||
| Day High | $344.72 | P/E | 51.92 | |||
| Day Low | $344.72 | EPS | $6.64 | |||
| Volume | 4,945 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 79.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $79.17 | 52 Week Low | $6.00 | |||
| Day High | $79.17 | P/E | N/A | |||
| Day Low | $79.17 | EPS | $-1.24 | |||
| Volume | 405 | |||||
